Immune molecules, including complement proteins C1q and C3, have emerged as critical mediators of synaptic refinement and plasticity. Complement localizes to synapses and refines the developing visual system through C3-dependent microglial phagocytosis of synapses. Retinal ganglion cells (RGCs) express C1q, the initiating protein of the classical complement cascade, during retinogeniculate refinement; however, the signals controlling C1q expression and function remain elusive. Previous work implicated an astrocyte-derived factor in regulating neuronal C1q expression. Here we identify retinal transforming growth factor (TGF)-b as a key regulator of neuronal C1q expression and synaptic pruning in the developing visual system. Mice lacking TGF-b receptor II (TGFbRII) in retinal neurons had reduced C1q expression in RGCs and reduced synaptic localization of complement, and phenocopied refinement defects observed in complement-deficient mice, including reduced eye-specific segregation and microglial engulfment of RGC inputs. These data implicate TGF-b in regulating neuronal C1q expression to initiate complement-and microglia-mediated synaptic pruning. 
Increasing evidence implicates immune molecules in synapse development and refinement. Several molecules best known for their functions in the immune system, including MHC class I (ref. 1), neuronal pentraxins 2 and complement 3 , mediate synaptic remodeling in the developing mouse brain, yet surprisingly little is known about the signals regulating the expression and function of these immune molecules at developing synapses.
Classical complement cascade proteins are components of the innate immune system that mediate developmental synaptic pruning, a process critical for the establishment of precise synaptic circuits. Complement proteins C1q and C3 are expressed in the postnatal brain and localize to subsets of synapses during synaptic remodeling in the mouse retinogeniculate system 3 -a classic model for studying developmental synapse elimination. Early in postnatal development, RGCs form transient functional synaptic connections with relay neurons in the dorsal lateral geniculate nucleus (dLGN). Before eye opening around postnatal day (P) 14, many of these transient retinogeniculate synapses are eliminated while the remaining synaptic arbors are elaborated and strengthened [4] [5] [6] . C1qa −/− and C3 −/− mice exhibit sustained defects in synaptic refinement and elimination, as shown by the failure to segregate into eye-specific territories and the retention of multi-innervated dLGN relay neurons 3 . However, the signals regulating complement-mediated pruning during development remain poorly understood.
As the initiator of the classical complement cascade, C1q is a critical point of regulation in this pathway. C1q, a large secreted protein composed of C1qA, C1qB and C1qC peptide chains, is the recognition domain of the initiating protein, C1, in the classical complement cascade. In the immune system, binding of C1q to apoptotic cell membranes or pathogens triggers a proteolytic cascade of downstream complement proteins, resulting in C3 opsonization and phagocytosis by macrophages that express complement receptors. The function of complement proteins in the brain appears analogous to their immune system function: clearance of cellular material that has been 'tagged' for elimination. Consistent with the well-ascribed role of complement proteins as opsonins, or "eat me" signals, C1q and C3 localize to retinogeniculate synapses, and presynaptic terminals of retinal ganglion cells are similarly eliminated by phagocytic microglia expressing complement receptors. Genetic elimination of C1q, C3 or the microgliaspecific complement receptor, CR3 (CD11b), results in sustained defects in eye-specific segregation 7 , suggesting that these molecules function in a common pathway to refine synaptic circuits 3, 7 . Notably, microglial engulfment of retinogeniculate inputs occurs during the narrow window of postnatal development (P5-P8) coincident with retinal C1q expression 3 , suggesting that complement-dependent synaptic pruning may be initiated by C1q in the developing brain.
Remarkably little is known about the signals controlling C1q expression and function in the brain. In contrast to microglia, which express C1q continuously throughout development, RGCs express C1q in a developmentally restricted manner peaking during the early postnatal period when RGC axons undergo synaptic pruning 3 . Given the developmental expression of C1q in RGC neurons, we posited that RGC-derived C1q may be key in refinement of RGC synapses onto their target neurons in the dLGN. We therefore sought to identify the signals regulating C1q expression in RGCs and to determine whether retinal C1q is required to initiate downstream complementdependent synaptic refinement and microglia-mediated synaptic pruning in the dLGN.
A screen investigating how astrocytes influence neuronal gene expression first identified the C1q genes among the few that were 1 7 7 4 VOLUME 16 | NUMBER 12 | DECEMBER 2013 nature neurOSCIenCe a r t I C l e S highly upregulated in developing RGCs in response to astrocytes 3 . The presence of immature astrocytes in the retina corresponds to C1q expression in RGCs in vivo, suggesting that the astrocyte-derived factor that upregulates C1q in RGC cultures also regulates postnatal C1q expression in RGCs in vivo. Each of the three C1q genes (C1qa, C1qb and C1qc) were found to be highly upregulated in purified RGCs upon exposure to a feeder layer of astrocytes 3 , implicating a secreted factor; however, the astrocyte-derived signal(s) that regulate C1q expression has not been identified. In the immune system, expression of complement and other immune genes can be modulated by rapid cytokine signaling pathways that regulate the inflammatory response. In the developing brain, astrocytes are a major source of cytokines, several of which potently regulate synapse development and function [8] [9] [10] [11] .
Here we identify transforming growth factor-β (TGF-β) as the factor secreted by astrocytes necessary and sufficient for C1q expression in purified RGCs. TGF-β ligands are expressed in the retina during the refinement period, and TGF-β receptors (TGFβRII) are developmentally expressed in the postnatal RGCs in vivo. Blocking TGF-β signaling in retinal neurons reduced C1q expression in postnatal RGCs and decreased synaptic localization of complement in the dLGN in vivo. Moreover, specific disruption of TGFβRII in retinal neurons inhibited complementand microglia-mediated synaptic pruning in the dLGN, suggesting that TGF-β-dependent regulation of neuronal C1q in the retina regulates downstream complement-dependent synapse elimination in the dLGN. Taken together, our data reveal a role for the TGF-β cytokine signaling pathway in regulating C1q expression in neurons and in initiating complement-dependent synaptic refinement in the developing CNS.
RESULTS

C1q upregulation by a secreted factor is rapid and direct
Previous findings suggested that an astrocyte-derived factor triggers neuronal C1q expression 3 . In agreement with previous findings, we found that purified RGC neurons significantly upregulated the expression of the C1q genes (C1qa, C1qb and C1qc) upon chronic exposure (6 d) to cortical astrocytes grown on tissue culture inserts suspended above cultured RGCs (Fig. 1a) . To determine whether C1q upregulation in RGCs was dependent on indirect, bidirectional signaling between astrocytes and neurons, we measured C1qb mRNA levels in purified P8 RGC cultures treated for 6 days in vitro (DIV) with conditioned medium collected from cortical astrocytes (ACM). Treating RGCs with ACM or astrocyte inserts resulted in a comparable 10-20 fold upregulation of C1q in RGCs (Fig. 1a) , suggesting that an astrocyte-secreted factor directly upregulates neuronal C1q expression. Moreover, ACM collected from purified P8 retinal astrocyte cultures 12 stimulated a similar upregulation compared to purified or standard cortical astrocytes (Fig. 1a) , suggesting that the astrocyte-derived factor that upregulates C1q in RGC cultures may also regulate C1q expression in RGCs in vivo.
Our results support a direct astrocyte-to-neuron signaling pathway in C1q upregulation; however, chronic exposure to astrocytes promotes many developmental changes in neurons, including robust increases in synapse number and neuronal activity 9, 13 . To determine the time course for C1q upregulation, we measured C1qa, C1qb and C1qc mRNAs by quantitative PCR (qPCR) after ACM treatment (15 min-3 d) . Surprisingly, RGCs upregulated C1q after only 15 min of ACM treatment, further supporting the idea that ACM directly triggers C1q upregulation (Fig. 1b) . Moreover, RGCs rapidly upregulated mRNAs for C1ra and C1s, encoding the enzymes that associate with C1q to initiate the complement cascade ( Supplementary  Fig. 1a ). This rapid upregulation occurred only in neurons and not in microglia or astrocytes treated with ACM for 15 min, suggesting differential regulatory mechanisms in neurons and glia (Fig. 1c) . C1qb upregulation was blocked by actinomycin, a transcriptional inhibitor, confirming that this effect was a result of transcription Figure 1 C1q is rapidly upregulated in neurons in response to astrocyte-secreted factors. (a) qPCR for C1qb showed increased C1qb expression relative to controls (RGCs treated with control medium) after 6 d treatment with astrocyte insert or astrocyteconditioned medium (ACM). ACM prepared from purified cortical astrocytes (cortical), purified retinal astrocytes (retinal) or astrocytes prepared using the McCarthy and Devellis protocol 43 (MD) all showed a similar upregulation (one-way ANOVA, n = 3 experiments, ****P < 0.0001, npg a r t I C l e S (Supplementary Fig. 1b) . Furthermore, boiling ACM destroyed its ability to induce C1qb upregulation, implicating a protein in ACM in neuronal C1q upregulation (Supplementary Fig. 1c ).
In addition to the upregulation of C1qa, C1qb and C1qc mRNAs, we observed a corresponding increase in C1qA protein as measured by western blot analysis of medium from cultures treated for 1 week with ACM ( Fig. 1d) and by immunocytochemistry for C1q (rabbit anti-C1qA 14 ) in purified RGC cultures treated with ACM (6 h) (Fig. 1e,f) . ACM itself or medium from RGCs treated with ACM acutely showed undetectable C1q by western blot (data not shown), indicating that C1q produced by RGCs accumulates in the medium over time in response to ACM. Thus, we used this purified culture system as a robust assay to screen for secreted signals that rapidly upregulate and sustain C1q expression in RGCs.
TGF-b is necessary and sufficient for C1q upregulation
To identify the astrocyte-derived factor responsible for C1q upregulation, we screened several candidate molecules for the ability to upregulate C1q in purified RGC neuronal cultures. Cytokines, potent modulators of immune and neural function, were the main class of molecule we tested because astrocytes are a major source of cytokines in the brain and several cytokines elicit systemic increases in C1q in the bloodstream. We first measured several candidate cytokines in ACM by ELISA (MSD mouse 7-plex inflammatory cytokine assay and individual ELISAs for TGF-β1, TGF-β2 and TGF-β3) (Fig. 2a) . Several cytokines were detected in ACM, including CXCL1, interleukin (IL)-12, TGF-β1, TGF-β2 and TGF-β3. To determine which cytokines were required for astrocyte-dependent C1q upregulation in RGC neurons, we immunodepleted individual cytokines from ACM. Two of the cytokines most enriched in ACM, CXCL1 and IL-12, showed no effect on C1qb expression when added to cultures as recombinant protein (Supplementary Fig. 1d,e) ; thus, we did not perform immunodepletion of these cytokines. Although tumor necrosis factor-α and IL-6 induced modest C1qb upregulation when added directly to RGC cultures (Supplementary Fig. 1f) , immunodepletion of these cytokines did not affect ACM-induced C1qb upregulation (Fig. 2b) . In contrast, specific immunodepletion of TGF-β from ACM using an anti-pan-TGF-β neutralizing antibody (1D11, R&D Systems) prevented ACM-induced C1qb upregulation after 15 min of treatment, as measured by qPCR (Fig. 2b) . We verified TGF-β immunodepletion from ACM by ELISA (Fig. 2c) . Together, these data show that TGF-β is necessary to upregulate neuronal C1q in purified RGC cultures.
To determine which TGF-β isoform was upregulating C1q expression, we depleted individual TGF-β isoforms from ACM using antibodies specific to TGF-β1, TGF-β2 or TGF-β3 (R&D Systems). Only ACM depleted of TGF-β3 failed to upregulate C1qb in RGCs, suggesting that this isoform may be key in regulating npg a r t I C l e S neuronal C1q (Fig. 2d) . Furthermore, we generated concentrationresponse curves (25 pg ml −1 -50 ng ml −1 ) in RGC cultures for each of the TGF-β isoforms and measured C1qb expression by qPCR. TGF-β3 most effectively upregulated C1qb in RGCs at concentrations similar to those measured in ACM, whereas TGF-β2 modestly upregulated C1qb at high concentrations ( Fig. 2e) . In addition, glycine elution to release ACM-derived bound TGF-β from anti-pan-TGF-β or anti-TGF-β3 neutralizing antibodies produced an eluate that could upregulate C1qb to the same extent as ACM when added to RGC cultures ( Fig. 2f) . We also found that retinal astrocytes showed enrichment for TGF-β3 when compared with RGCs, cortical astrocytes and microglia ( Supplementary Fig. 1g ). However, treating retinal astrocyte or microglial cultures with recombinant TGF-β3 (50 pg ml −1 , 15 min) failed to induce C1qb upregulation ( Fig. 2g ), in agreement with our findings with ACM treatment (Fig. 1c) . Taken together, these results demonstrate that, of the cytokines tested, TGF-β is a major component in ACM responsible for C1q upregulation in RGCs but not in microglia or astrocytes (Fig. 2g) . Furthermore, our findings suggest that TGF-β3 may be the key isoform regulating C1q expression in RGCs (Fig. 2d,f) . We next addressed whether TGF-β receptor signaling in RGCs is required for C1q upregulation in RGCs. In the canonical TGF-β signaling pathway, TGF-β1, TGF-β2 or TGF-β3 binds to TGFβRII, which then phosphorylates TGFβRI. Once activated, TGFβRI phosphorylates a Smad transcription factor to alter gene expression. A third receptor, TGFβRIII, can also associate with TGFβRII, and it alters ligand affinity 15 . Purified RGCs express all of the components required for TGF-β signaling (Fig. 2h,i) . Furthermore, treating RGCs with ACM stimulated rapid (15-30 min) nuclear accumulation of phosphorylated Smads 2 and/or 3 (pSmad2/3), as measured by immunocytochemistry (Fig. 2h) , which is consistent with the timing of C1q upregulation. In addition, transcripts for TGFβRII, TGFβRIII and TGFβRI were present in purified RGCs (Fig. 2i) . These data indicate that RGCs express functional TGF-β receptors that can be activated with a time course consistent with that of C1q upregulation.
To determine whether the TGF-β receptors TGF-βRI and TGF-βRII were responsible for this upregulation, we preincubated RGC cultures with specific inhibitors of TGFβRI and TGFβRII before acute treatment with either TGF-β3 (50 pg ml −1 ) or ACM. Adding TGFβRII neutralizing antibodies (R&D Systems) or a TGFβRI-specific inhibitor 16 (SB431542, Tocris, 30 µM) blocked both TGF-β-induced and ACM-induced C1q upregulation (Fig. 2j) . Thus, signaling through TGFβRI and TGFβRII is required for ACM-induced C1q upregulation in purified RGCs.
TGF-b regulates developmental C1q expression in the retina
C1q is developmentally regulated in the postnatal retina, showing peak expression around P5 and sharply decreasing by P10-P15 (ref. 3) , corresponding to the synaptic refinement period in the retinogeniculate system and the presence of immature astrocytes throughout the developing CNS (Supplementary Fig. 2a) . To determine whether TGF-β signaling regulates developmental C1q expression in RGCs in vivo, we examined the expression of TGF-β signaling components during the refinement period. We detected expression of all three isoforms of Tgfb by reverse transcription (RT)-PCR at P5 and in the mature retina (Fig. 3a) . In addition, we detected TGFβRII protein in retinal lysates by western blot (Fig. 3b) . Of the three ages examined, the level of TGFβRII protein was highest at P5 and sharply decreased by P15 and P28 (Fig. 3b,c) , coinciding with C1q expression in the postnatal retina (Supplementary Fig. 2a ). In agreement with western blot analysis, immunohistochemistry for TGFβRII showed TGFβRII localization to the RGC and inner plexiform layers (IPL) of the retina at P5 and a decrease in TGFβRII by P15 (Fig. 3d) . Co-staining with anti-calretinin (Millipore), a marker of a subset of RGCs, confirmed TGFβRII localization to RGCs (Supplementary Fig. 2b ). Taken together, these data show that TGF-β ligands and receptors are present at the right time in the retina to regulate C1q expression.
To determine whether TGF-β signaling regulates C1q expression in vivo during retinogeniculate refinement, we used genetic and pharmacological approaches to block TGF-β signaling and then measured C1q expression in vivo. Retina-specific Tgfbr2 −/− mice were generated by crossing mice with a loxP-flanked Tgfbr2 gene with mice expressing Cre recombinase under the control of the mouse Chx10 (also known as Vsx2) promoter, which is active at embryonic day 13.5 in the outer neuroblastic layer of the retina only 17, 18 . TGFβRII knockout was confirmed by immunostaining retinas (Fig. 3d) and performing RT-PCR using mRNA from wild-type (WT) and transgenic P5 whole brain (Supplementary Fig. 2c ) and purified RGCs acutely isolated from P5 WT and transgenic mice (Fig. 3e) . Klf10 (Tieg), whose expression is known to be TGF-β dependent, also showed reduced expression in P5 acutely isolated RGCs (Supplementary Fig. 2d) . Moreover, while total Smad2 levels were not significantly different between WT and retinal Tgfbr2 −/− mice (Fig. 3f) , pSmad2/3 levels, corresponding to active TGF-β signaling, were reduced in RGCs identified by co-staining with Brn3a, a POU-domain transcription factor specific to this cell type (Fig. 3g) , further indicating that TGFβRII retina-specific knockout was achieved. Because TGF-β signaling has many roles in development, we measured cell numbers, axon density and axon caliber and found no significant difference from WT retinas ( Supplementary Fig. 2e-h ). Given that there were no gross abnormalities in retinal development, we used this mouse to analyze the role of TGF-β signaling in C1q regulation and synaptic refinement.
To determine whether retinal TGF-β signaling is required for developmental C1q expression in RGCs, we assayed C1q expression levels in retinas and RGCs from retinal Tgfbr2 −/− mice relative to those in WT littermates and from mice receiving intravitreal injection of anti-TGF-β relative to those in vehicle-treated littermates. In situ hybridization for C1qb revealed a decrease in signal for C1qb in the RGC layer in retinal Tgfbr2 −/− retinas (P5) compared to that in WT littermates ( Fig. 4a; anti-TGF-β, Supplementary Fig. 3a) . To verify that reduction in C1q expression was in RGCs and not other cell types in the RGC layer, we acutely isolated RGCs and microglia from P5 retinas using established immunopanning techniques 12, 19 .
Acutely isolated RGCs from the retinal Tgfbr2 −/− mice showed a significant reduction in C1qb expression by qPCR, whereas acutely isolated retinal microglia did not (Fig. 4b) , as expected given that microglia do not express Chx10. Similarly, RGCs acutely isolated from P5 mice receiving intravitreal injection at P3 of anti-TGF-β also showed significantly reduced C1qb expression, whereas microglia again showed no change in C1q (two-way ANOVA, n = 4 mice per group, P < 0.05, F 2,18 = 7.108; Supplementary Fig. 3b) . We verified cell purity after immunopanning using qPCR for the neuronspecific mRNA Eno2 (Nse) and the microglia-specific mRNA Iba1 (Supplementary Fig. 3c) . Moreover, immunohistochemistry for C1q at P5 in retinal Tgfbr2 −/− (Fig. 4c,d ) and anti-TGF-β-injected mice (Supplementary Fig. 3d,e) also showed a 40-50% reduction in C1q immunostaining in the IPL and RGC layers of the retina but showed no change in microglial staining. Taken together, these data show that TGF-β signaling is required for postnatal C1q expression in RGCs. These results also suggest that TGF-β regulation of C1q may be restricted to neurons, as suggested by our earlier in vitro data (Fig. 1c) .
Retinal TGF-b regulates complement levels in the thalamus C1q and C3 localize to synapses in the dLGN during the period of synaptic refinement, but whether RGC neurons are a key source of C1q in the dLGN is not known. One possibility is that neuronal C1q is locally secreted from RGC axons into the dLGN to initiate complement-dependent synaptic pruning. Alternatively, microglia, although sparse in the dLGN at this time, may be a primary source of secreted C1q in the postnatal dLGN during refinement. To address this question, we examined C1q protein levels by immunohistochemistry in cross-sections of P5 optic nerve. C1q could be detected in optic nerve fiber bundles, identified by TUJ1 staining. Moreover, C1q immunoreactivity in the optic nerve was significantly reduced in (Fig. 4e,f) , suggesting that TGF-β signaling in RGCs regulates C1q in RGC axons in the optic nerve.
If C1q in the dLGN is supplied by RGCs, we predicted that retinal Tgfbr2 −/− mice would have a reduction in C1q protein throughout the dLGN. Indeed, immunohistochemistry for C1q revealed a significant decrease in the intensity of C1q staining in the dLGN but not in primary visual cortex (V1) (Fig. 5a) , which is not a direct target for RGCs. Quantification showed a significant reduction in fluorescence intensity in the retinal Tgfbr2 −/− mice, as well as a significant decrease in the density of C1q puncta in the dLGN but not in V1 (Fig. 5b,c) , indicating that RGC axons are a key source of C1q in the postnatal dLGN.
Given previous findings that C1q and C3 localize to synapses in the dLGN, we examined synaptic localization of complement in the dLGN in retinal Tgfbr2 −/− mice and WT littermates to determine whether synaptic localization of these proteins depends on retinal TGF-β signaling. Immunostaining in the dLGN using antibodies to C1q, C3 and vesicular glutamate transporter 2 (vglut2) to label RGC terminals showed approximately 15% of vglut2-positive puncta co-labeled with C1q (Fig. 5d,e) and ~25% of vglut2 puncta co-stained with the downstream complement protein, C3 (Fig. 5f,g ). The increase in the number of RGC terminals labeled with C3 versus C1q is consistent with the placement of these molecules in the classical complement cascade, as multiple C3 molecules can be activated downstream of a single C1q molecule. Also, as expected given that C1q is upstream of C3 activation in the complement cascade, we found that C3 deposition in the dLGN was undetectable in the C1q −/− mouse ( Supplementary  Fig. 3f ). In retinal Tgfbr2 −/− dLGNs, we also observed a significant reduction in synaptic localization of both C1q and C3 (Fig. 5d-g ).
Given that retinal Tgfbr2 −/− exhibit specific reduction in TGF-β signaling and C1q in the retina, a reduction in C1q and C3 synaptic localization in the dLGN suggests that an appreciable fraction of synaptically localized C1q is supplied by RGC terminals and that C1q and C3 localization to synapses is dependent on retinal TGF-β signaling. Thus, local microglia-derived C1q in the dLGN does not appear to localize to synapses to compensate for the loss of RGC-derived C1q.
TGF-b signaling is required for eye-specific segregation
In C1qa −/− mice, RGC axons do not segregate into eye-specific territories normally as assessed by anterograde tracing techniques 3 . If C1q supplied by RGC axons is required for eye-specific segregation and if retinal TGF-β signaling regulates C1q expression, then retinal Tgfbr2 −/− mice should exhibit a phenotype similar to that of C1qa −/− mice. To test this hypothesis, we used established anterograde tracing techniques to visualize the formation of eye-specific territories in the dLGN and to assay eye-specific segregation in retinal Tgfbr2 −/− mice and in mice injected with anti-TGF-β. Mice received intraocular injections of cholera toxin-β conjugated to Alexa 488 or Alexa 594 (CTB-488 or CTB-594) at P9 in the left and right eyes, respectively, and mice were sacrificed at P10. We assayed eye-specific segregation using an unbiased assay in which the degree of segregation is represented by the variance of the distribution of the R value, the logarithm of the ratio of fluorescence intensity (F) from each fluorescence channel (that is, R = log 10 (F ipsi /F contra )) 20 . Using this assay, high variance signifies a high degree of segregation in the dLGN, while low variance corresponds to increased overlap between contralateral and ipsilateral territories. Our results showed a significantly lower variance in C1qa −/− mice than in WT controls, as expected (Fig. 6a,b) . Notably, we observed a similar phenotype in retinal Tgfbr2 −/− mice (Fig. 6a,b) 
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Retinal Tgfbr2 a r t I C l e S and mice injected with anti-TGF-β (Fig. 6a,c) , suggesting a common pathway. Defects in eye-specific segregation were confirmed by also quantifying the percentage of dLGN area innervated by both contralateral and ipsilateral RGC inputs (Fig. 7a,b) . Measurement of dLGN area showed no difference between WT and retinal Tgfbr2 −/− (Fig. 7c) , and we detected no difference in dLGN relay neuron number (data not shown), determined by immunohistochemistry for unphosphorylated neurofilament (SMI-32), in retinal Tgfbr2 −/− mice as compared to WT. Our results showed that retinal TGF-β was required for eye-specific segregation, but it was not clear whether this effect occurred through regulation of C1q. To determine whether TGF-β could regulate synaptic refinement independently of C1q, we performed 
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Retinal Tgfbr2 a r t I C l e S intraocular injection of anti-TGF-β neutralizing antibodies in WT and C1qa −/− animals to determine whether blocking TGF-β would disrupt synaptic refinement in the absence of C1q. If TGF-β and C1q regulate pruning by different mechanisms, blocking TGF-β in C1qa −/− mice should produce a more severe segregation defect, or increased overlap, than that in vehicle-injected C1aq −/− mice. If TGF-β and C1q are in the same pathway, blocking TGF-β signaling in the C1qa −/− mouse should have no effect. Blocking TGF-β in the C1qa −/− mouse did not result in a more severe phenotype, which is consistent with TGF-β exerting its effect on synaptic refinement via regulation of C1q (Figs. 6a-c and  7a,b) . Taken together, these results show that retinal TGF-β signaling is required for eye-specific segregation and that TGF-β and C1q likely work in the same pathway to regulate this process.
Retinal TGF-b and C1q regulate microglia-mediated pruning Engulfment of retinogeniculate synapses by microglia is thought to be the final step in complement-dependent synapse elimination. Recent work has demonstrated that microglia engulf RGC terminals in the dLGN during the pruning period in a complement (C3-CR3)-dependent manner 7 . Therefore, if RGC-derived C1q regulates this process, we predict retinal Tgfbr2 −/− mice to show a reduction in microglial engulfment of RGC terminals.
To test this hypothesis, we used an established microglia engulfment assay 7 to quantify microglial phagocytosis of RGC inputs in C1qa −/− mice and retinal Tgfbr2 −/− mice. We found a significant reduction in microglial engulfment of RGC inputs at P5 in C1qa −/− and Tgfbr2 −/− mice as compared to littermate controls (Fig. 6d) . We found no differences in the number, distribution or activation state of microglia in the dLGN in WT versus C1qa −/− or Tgfbr2 −/− conditions ( Supplementary Fig. 4a-d) . These results show that reduction of retinal TGF-β signaling, and consequently of C1q expression in RGCs, reduces microglial phagocytosis of RGC terminals in the dLGN. Together these data support the hypothesis that RGC-derived C1q is required to initiate the process of complement-dependent synapse elimination by microglia.
DISCUSSION
This study establishes that TGF-β signaling in RGC neurons plays a key role in refinement of RGC synapses on their target relay neurons in the dLGN by regulating expression of C1q, the initiating protein of the classical complement cascade. We demonstrate that TGF-β signaling is necessary and sufficient for transcriptional upregulation of C1q in purified RGCs (Fig. 2) . In agreement with in vitro studies, conditional knockout of TGFβRII in retinal neurons reduced C1q expression in RGCs during the period of active refinement of retinogeniculate synapses in the thalamus (Fig. 4) . Furthermore, our data show that C1q and C3 localization to synapses in the dLGN during retinogeniculate refinement is dependent on retinal TGF-β signaling (Fig. 5) . Inhibition of TGF-β signaling in the postnatal retina resulted in defects in eye-specific segregation in the dLGN, mimicking the phenotype observed in global C1qa −/− mice (Fig. 6a-c) . We also observed defects in microglial engulfment of RGC terminals (Fig. 6d) , which phenocopied the C3 −/− and CR3 −/− (Itgam −/− ) mouse microglial engulfment defects 7 . Taken together, our findings support a model in which retinal TGF-β signaling controls C1q expression in RGCs and local C1q release in the dLGN to regulate microglia-mediated, complement-dependent synaptic refinement (Supplementary Fig. 5 ).
C1q regulates microglia-mediated pruning in the thalamus
Emerging evidence implicates microglia in developmental synaptic refinement 7, 21, 22 ; however, the mechanisms controlling the timing and location of microglia-mediated synaptic refinement in the brain are poorly understood. Process-bearing phagocytic microglia in the postnatal dLGN engulf RGC inputs during retinogeniculate refinement in a manner dependent on complement C3-CR3 signaling and neuronal activity 7 . Upon complement cascade activation, C3 is cleaved to form the potent opsonin C3b, a ligand for the phagocytic complement receptor CR3 expressed in the brain by microglia exclusively. Thus, as the initiator of the classical complement cascade, C1q is a critical regulator of C3 activation and C3-dependent phagocytosis. Our results suggest that C3 localization to synapses (Fig. 5) and microglia-mediated pruning (Fig. 6) depend on retina-derived C1q. Specifically, we observed a decrease in C3 localization to synapses in C1qa −/− and in retinal Tgfbr2 −/− mice. We also found that microglial engulfment of RGC terminals is decreased in C1qa −/− (Fig. 6d) and in retinal Tgfbr2 −/− mice (Fig. 6d) , placing retina-derived C1q and retinal TGF-β signaling upstream of this process.
Interestingly, recent work revealed that microglia-mediated pruning is regulated by neuronal activity 7 . During the retinogeniculate pruning period, microglia preferentially engulf less active RGC inputs in the dLGN 7 , suggesting that microglia can sense or read out local changes in synaptic activity. The engulfment defects observed in complement-deficient mice and the role for complement in the immune system suggest the intriguing possibility that complement proteins could be one cue guiding microglia to engulf less active synapses. Other immune molecules implicated in synaptic refinement, such as MHC class I (ref. 23 ) and neural pentraxins 24 , show activity-dependent transcriptional regulation, but whether these molecules influence activity-dependent microglial engulfment is unknown. Interestingly, C1q expression corresponds to the onset of spontaneous neuronal activity in the retina, and the C1qa −/− phenotype closely mimics the phenotype observed when spontaneous activity is disrupted in the retina. Whether and how neuronal activity regulates complement expression and function are open areas of investigation; however, on the basis of our data, we envision a model in which C1q is secreted locally from RGC terminals in an activity-dependent manner to regulate C3-CR3-dependent microglial synaptic phagocytosis (Supplementary Fig. 5 ).
Retinal C1q is required for retinogeniculate refinement In the postnatal retinogeniculate system, both RGCs and microglia express C1q. Although microglia express more C1q than neurons (Figs. 1c and 2g) , several lines of evidence suggest that RGCs contribute appreciably to C1q levels and complement-dependent synaptic refinement in the postnatal dLGN. In retinal Tgfbr2 −/− mice, which have reduced retinal C1q expression but normal microglial C1q expression, we observed defects in retinogeniculate refinement and microglial engulfment (Figs. 6 and 7) , suggesting that microglial C1q expression cannot compensate functionally for the loss of RGCderived C1q in complement-dependent synaptic refinement.
If RGC inputs are a critical source of C1q in the dLGN during synaptic refinement, how does C1q reach RGC terminals in the dLGN, far from the cell bodies in the retina? C1q is a large glycoprotein packaged and secreted by macrophages via traditional secretory pathways in the Golgi 25 . C1q then is secreted directly into the bloodstream by circulating macrophages. In RGCs, however, proteins that are produced and packaged in the soma in the retina have a long distance to travel to axon terminals in the dLGN. Given that in the retinal Tgfbr2 −/− mice we observed reduced C1q levels compared to those in WT mice in the retina (Fig. 4a-d) , the optic nerve (Fig. 4e,f) and the dLGN (Fig. 5) , we hypothesize that C1q is transported along RGC axons to the dLGN in secretory vesicles, per its packaging and secretion npg a r t I C l e S in macrophages. Alternatively, local translation and synthesis of C1q within RGC axons in the optic nerve or the dLGN is possible, although there have been no previous reports of local translation of C1q. Given the importance of spontaneous retinal activity in driving synaptic refinement and given that C1q regulation by TGF-β seems to be restricted to neurons (Figs. 1c and 4b) , we speculate that C1q secretion from RGC inputs may be regulated by neuronal activity and act as a molecular cue linking information about the retina to the dLGN to drive proper circuit development.
TGF-b: regulating neuronal C1q and CNS development
In the immune system, TGF-β is characterized as an anti-inflammatory cytokine that dampens the immune response. In the mammalian nervous system, TGF-β signaling pathways regulate diverse developmental processes, including neuronal survival and programmed cell death, axon specification, and synaptogenesis. TGF-β signaling modulates embryonic and postnatal periods of programmed cell death in the mouse retina 26 and also amplifies the efficacy of neurotrophic factors critical for cell survival, such as glia-derived neurotrophic factor 27 . In the developing rodent neocortex, TGF-β signaling is necessary and sufficient for axon specification 28 . Recent work also has shown that TGF-β regulates synaptogenesis in cortical neurons in vitro 29 and at the Drosophila melanogaster and Xenopus laevis neuromuscular junctions (NMJs) 30 . At the Drosophila NMJ, glia produce ligands that are TGF-β family members 31 , and they direct synaptogenesis by regulating a neuron-derived TGF-β family member and the downstream Rac guanine nucleotide exchange factor Trio 32 . Also in Drosophila, TGF-β directs large-scale neuronal and axonal remodeling during metamorphosis 33, 34 . TGF-β also affects synaptic function at excitatory and inhibitory synapses in the preBötzinger complex in the mouse brainstem 35 and modulates sensory neuron excitability and synaptic efficacy at sensorimotor synapses in the sea slug Aplysia 36 .
In the present study, we found that TGF-β signaling in postnatal RGCs was required for developmental synaptic refinement. Given the many important roles of TGF-β in development, we characterized other aspects of retinal development and found no significant deficits in the retinal Tgfbr2 −/− mouse. Disrupting TGFβRII in the retina did not dramatically affect the number of retinal neurons or retinal morphology. Moreover, despite the role for TGFβRII in axon specification in cortex, disruption of TGFβRII signaling in the retina did not alter axon specification in the retina or axon caliber in the optic nerve ( Supplementary Fig. 2f-h) , suggesting that other mechanisms underlie axon development and specification in RGCs. Although we have not quantified synapses in the dLGN of retinal Tgfbr2 −/− mice, it is unlikely that defective synaptogenesis could explain our phenotype, as we observed an increase in overlap between eye-specific territories. Furthermore, previous studies have reported that TGF-β is not synaptogenic in RGC cultures 10 , further supporting the idea that synaptogenesis is likely normal in these mice.
Together our data implicate TGF-β as a key regulator of synaptic refinement in the mammalian CNS. In Drosophila, a class of TGF-β family members together with an immunoglobulin superfamily member protein, Plum, has been implicated in the dramatic remodeling that occurs during metamorphosis in the CNS and at the NMJ 33, 34 . This finding combined with our findings raises the question of whether TGF-β signaling represents an important signal for synaptic remodeling throughout the nervous system. Could TGF-β initiate a synaptic refinement gene program in RGCs or other neurons that undergo refinement? Interestingly, C1q and TGF-β expression are expressed in the auditory system in embryonic and postnatal spiral ganglion neurons 37 around the time when spiral ganglion cell inputs onto outer hair cells are refined 38 . Little is known about the synaptic refinement mechanisms in the auditory system; however, this developmental expression of C1q and TGF-β suggests that the same mechanism for synapse elimination may drive refinement in both the auditory and visual systems. In both of these systems, C1q expression in sensory neurons (RGCs and spiral ganglion neurons) is developmentally regulated and restricted to periods of developmental synaptic remodeling. These findings are consistent with our hypothesis that neuron-derived C1q is critical for synaptic refinement, although it remains unclear whether TGF-β regulates C1q or other refinement genes in other brain regions.
Implications of TGF-b regulation of C1q in disease Our findings also have important implications for understanding the mechanisms underlying synapse elimination in the diseased brain. Dysregulation of immune system components, including complement proteins and cytokines, has been demonstrated in many CNS disorders, including epilepsy, schizophrenia and neurodegenerative diseases such as glaucoma and Alzheimer's disease. In particular, TGF-β localizes to β-amyloid plaques and has been linked to the formation of these plaques in Alzheimer's disease 39 , and blocking TGF-β and Smad2/3 signaling mitigates plaque formation in Alzheimer's mouse models 40 . C1q associates with plaques in Alzheimer's brains as well 41 , and in mouse models of Alzheimer's, C1q-deficiency has been shown to be neuroprotective 42 . Synapse loss and/or dysfunction have emerged as early hallmarks of neurodegenerative diseases, suggesting that aberrant complement upregulation may reactivate the developmental synapse elimination pathway in disease to promote synapse loss. Our work demonstrating a new link between TGF-β signaling, complement and synapse elimination opens new avenues of investigation into the role of this regulatory mechanism for C1q in these disorders and in other regions of the healthy CNS during development.
METHODS
Methods and any associated references are available in the online version of the paper. 4-8 fields were imaged in the contralateral territory (minimum of 8 fields per dLGN, 16 fields per animal). Subsequent images were processed and quantified using ImageJ (NIH) and Imaris software (Bitplane). For subsequent acquired z-stacks, ImageJ (NIH) was used to subtract background from all fluorescence channels (rolling ball radius = 10) and a mean filter was used for the EGFP channel (stained for Iba1) of 1.5. Subsequently, Imaris software (Bitplane) was used to create 3D volume surface renderings of each z-stack. Surface rendered images were used to determine the volume of the microglia, all RGC inputs and the volume of C1q staining. To visualize and measure the volume of engulfed inputs, any fluorescence that was not within the microglia volume was subtracted from the image using the mask function. The remaining engulfed/internal fluorescence was surface rendered using parameters previously determined for all RGC inputs/C1q and total volume of engulfed/internal inputs was calculated. To determine percentage engulfment (or percentage C1q-positive terminals), the following calculation was used: volume of internalized RGC input (or volume of C1q)/volume microglial cell (or RGC inputs). For KO engulfment experiments, all analyses were performed blind. microglia density quantification. For quantification of cell density, dLGNs from two coronal sections were imaged for each animal (n = 3 per treatment condition or genotype). To capture the entire dLGN, a 10× field was acquired. Microglia were subsequently counted from each 10× field. To calculate the density of microglia, the area of the dLGN was measured using ImageJ software (NIH). All analyses were performed blind to genotype or drug treatment.
Quantification of microglial activation state. Activation state was quantified based on established methods described in ref. 7 . Immunohistochemistry was performed on 40-µm cryosections with antibodies against Iba1 (Wako, rabbit anti-Iba1, cat. no. 019-19741, validated in ref. 7) and CD68 (Serotec, cat. no. MCA1957, validated in ref. 7) . For each genotype, two 20× fields of view were analyzed on a spinning-disk confocal microscope using 2-µm z-steps. The activation state was then determined using a maximum intensity projection. Iba1 staining was used to assess morphology on the basis of the number of branches, and the expression pattern of CD68 was analyzed and scored as 0 (no or scarce expression), 1 (punctate expression) or 2 (aggregated expression or punctate expression all over the cell). Scores from 0 to 3 for number of branches or 0 to
